The results of the distribution of KM survival curves showed that the median survival time (MS) of the GPX2 high expression group (MS = 3.3) was significantly lower than that of the GPX2 low expression group (MS = 4.1), and the overall survival rate (OS) of patients with high GPX2 expression was significantly lower than that in the low GPX2 expression group (P=0.0459, Figure 2(b)) suggesting that high GPX2 expression is associated with poor prognosis in patients with lung adenocarcinoma. This evidence concerns the gene GPX2 and lung adenocarcinoma.